Jump Financial LLC Lowers Position in Kenvue Inc. (NYSE:KVUE)

Jump Financial LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,879 shares of the company's stock after selling 15,680 shares during the period. Jump Financial LLC's holdings in Kenvue were worth $659,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Grove Bank & Trust increased its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the fourth quarter worth $29,000. SRS Capital Advisors Inc. increased its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC increased its holdings in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.5 %

Shares of Kenvue stock traded up $0.11 during trading on Monday, reaching $23.12. 12,011,898 shares of the stock were exchanged, compared to its average volume of 17,099,284. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average is $23.04 and its 200 day moving average is $22.46. The firm has a market cap of $44.36 billion, a price-to-earnings ratio of 43.62, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. Evercore ISI initiated coverage on shares of Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, Barclays reduced their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Monday, April 14th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average price target of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.